Abstract
Cyclins and CDKs play critical roles in DNA synthesis and cell division. Alterations in their function may lead to the disruption of normal cell growth and apoptosis, and subsequently, result in carcinogenesis. Elevated levels of cyclins and CDKs are frequently observed in a wide range of different types of human cancers. Understanding of molecular mechanisms underlying the cell cycle effects in response to the chemotherapeutic agents is of great importance for improving the efficacy of targeted therapeutics and overcoming resistance to chemotherapeutic agents. Despite the clinical applications of cell cycle specific chemotherapeutic agents, there is still an urgent need to develop novel drugs that can target multiple sites and pathways of the cell cycle while avoiding drug induced cytotoxicity. In this review article, we will summarize the development of novel agents that specifically target cell cycle pathways in human cancer. We will discuss drugs that can directly interfere with the mitotic process of tumor cells. Moreover, we tend to address the significance of using small molecule CDK inhibitors that are derived from natural products.
Keywords: Cell cycle, cyclins, CDKs, CDK inhibitors, cancer therapeutic targets
Anti-Cancer Agents in Medicinal Chemistry
Title: Cancer Therapy: Targeting Cell Cycle Regulators
Volume: 8 Issue: 7
Author(s): Martin Johansson and Jenny Liao Persson
Affiliation:
Keywords: Cell cycle, cyclins, CDKs, CDK inhibitors, cancer therapeutic targets
Abstract: Cyclins and CDKs play critical roles in DNA synthesis and cell division. Alterations in their function may lead to the disruption of normal cell growth and apoptosis, and subsequently, result in carcinogenesis. Elevated levels of cyclins and CDKs are frequently observed in a wide range of different types of human cancers. Understanding of molecular mechanisms underlying the cell cycle effects in response to the chemotherapeutic agents is of great importance for improving the efficacy of targeted therapeutics and overcoming resistance to chemotherapeutic agents. Despite the clinical applications of cell cycle specific chemotherapeutic agents, there is still an urgent need to develop novel drugs that can target multiple sites and pathways of the cell cycle while avoiding drug induced cytotoxicity. In this review article, we will summarize the development of novel agents that specifically target cell cycle pathways in human cancer. We will discuss drugs that can directly interfere with the mitotic process of tumor cells. Moreover, we tend to address the significance of using small molecule CDK inhibitors that are derived from natural products.
Export Options
About this article
Cite this article as:
Johansson Martin and Persson Liao Jenny, Cancer Therapy: Targeting Cell Cycle Regulators, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (7) . https://dx.doi.org/10.2174/187152008785914833
DOI https://dx.doi.org/10.2174/187152008785914833 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Laboratory Diagnosis and Therapy of Invasive Fungal Infections
Current Drug Targets Site-related Effects of Relaxin in the Gastrointestinal Tract Through Nitric Oxide Signalling: An Updated Report
Current Protein & Peptide Science Antioxidant Effect of Flavonoids Present in Euterpe oleracea Martius and Neurodegenerative Diseases: A Literature Review
Central Nervous System Agents in Medicinal Chemistry Recent Patents of DNA Methylation Biomarkers in Gastrointestinal Oncology
Recent Patents on DNA & Gene Sequences Biotechnological Applications of Trametes versicolor and their Enzymes
Current Biotechnology Advances in Hydrogels Applied to Degenerative Diseases
Current Pharmaceutical Design Recent Advances in Optical Cancer Imaging of EGF Receptors
Current Medicinal Chemistry Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer
Current Pharmaceutical Design Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry Pretreatment Serum Fibrinogen Levels are Associated with Postoperative Distant Metastasis and Prognosis of Resected Lung Cancer Patient: A Retrospective Study
Current Signal Transduction Therapy Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors
Current Clinical Pharmacology Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets TGF-β Signaling in Gastrointestinal Cancer Stem Cells
Current Cancer Therapy Reviews Dendritic Cells in Esophageal Adenocarcinoma: The Currently Available Information and Possibilities to use Dendritic Cells for Immunotherapeutic Approaches
Current Pharmaceutical Design Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy
Current Medicinal Chemistry Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA Rikkunshito and Ghrelin Secretion
Current Pharmaceutical Design The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer
Current Medicinal Chemistry